Traditional Chinese medicine composition for treating mycoplasma pneumonia

Abstract

The invention discloses a traditional Chinese medicine composition for treating mycoplasma pneumonia. The traditional Chinese medicine composition includes the following raw materials, by weight, 10-30 parts of leaves of platycladus orientalis, 10-20 parts of radix asteris, 5-15 parts of folium isatidis, 10-20 parts of radix ophiopogonis, 10-20 parts of duckweed, 10-20 parts of rhizoma phragmitis, 5-15 parts of cortex mori radicis, 10-20 parts of ephedra, 10-20 parts of herba andrographitis, 5-15 parts of bulbus fritillariae cirrhosae, 10-20 parts of radix scrophulariae, 10-20 parts of radix isatidis, 10-20 parts of spiked aletris, 5-15 parts of ardisia japonica, 10-20 parts of lily, 10-20 parts of stachys sieboldii, 10-20 parts of houttuynia cordata, 10-20 parts of codonopsis pilosula, 5-15 parts of rhodiola rosea, 10-20 parts of honeysuckle, 10-20 parts of momordica grosvenori, 10-20 parts of brassica juncea and 5-15 parts of liquorice. The traditional Chinese medicine composition has the effects of clearing heat and purging heat, dispelling the evil and detoxifying body, relieving inflammation and relieving cough, diffusing lung and dispelling phlegm, has significant effects in treatment of the mycoplasma pneumonia and has reliable effects.

Description

technical field [0001] The invention relates to a medical preparation of an undetermined structure of traditional herbal medicine, in particular to a traditional Chinese medicine composition for treating mycoplasma pneumonia. Background technique [0002] Mycoplasma pneumonia is pneumonia caused by Mycoplasma pneumoniae, once called primary atypical pneumonia. The onset of the disease is slow, with fever, paroxysmal irritating cough, and a small amount of mucus or mucopurulent sputum (occasionally bloody sputum). Pulmonary signs are often not obvious, but it is easy to cause involvement of multiple extrapulmonary systems, which can also threaten life or death. It tends to occur in children or adolescents, especially in places where people gather, such as families and schools. It accounts for 15-30% of the total number of pneumonias. It generally has a good prognosis and is a self-limiting disease. At present, the clinical treatment of mycoplasma pneumonia is mostly treated...

AI Technical Summary

Problems solved by technology

Although the above-mentioned drugs are effective in treating mycoplasma pneumonia, they have large side effects